China Grand Pharmaceutical and Healthcare Holdings Ltd. entered into a licensing agreement with Biohit Oyj in relation to the provision of right from Biohit to Grand Pharm (China) to use the intellectual property rights and know-how of Biohit to exclusively manufacture and distribute the acetaldehyde binding products developed by Biohit in China. Grand Pharm (China) has expressed its interest to co-operate with Biohit, and is prepared to commercialize the innovative acetaldehyde binding products to the market in China subject to further negotiation and agreements with Biohit.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.81 HKD | +0.84% |
|
+1.26% | +17.60% |
Jun. 24 | Grand Pharmaceutical Group Limited Announces Executive Changes | CI |
Jun. 12 | Grand Pharmaceutical Group Enrolls First Patient in Phase 1 Study for Myopia Eye Drops in China | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.60% | 2.16B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- 512 Stock
- News Grand Pharmaceutical Group Limited
- China Grand Pharmaceutical and Healthcare Holdings Ltd. Enters into a Licensing Agreement with Biohit Oyj